ESCRS - O50 - BELANTAMAB ASSOCIATED SUPERFICIAL KERATOPATHY IN A SERIES OF PATIENTS

BELANTAMAB ASSOCIATED SUPERFICIAL KERATOPATHY IN A SERIES OF PATIENTS

Published 2023 - 27th ESCRS Winter Meeting

Reference: O50 | Type: Free Paper Submission | DOI: 10.82333/0rcd-sp10

Authors: Panagiota Ntonti* 1 , Niki Xanthopoulou 1 , Eirini-Kanella Panagiotopoulou 1 , Minas Bakirtzis 1 , Emmanouil Spanoudakis 2 , Zoi Bezirgiannidou 2 , Konstantinos Liapis 2 , Georgios Labiris 1

1Ophthalmology,Democritus University of Thrace,Alexandroupolis,Greece, 2Hematology,Democritus University of Thrace,Alexandroupolis,Greece

Purpose

To describe structural changes in corneal epithelium of patients receiving monotherapy with Belantamab mafodotin (belamaf; GSK2857916) within the treatment of relapsed and refractory multiple myeloma (RRMM).

Setting

Department of Ophthalmology, University Hospital of Alexandroupolis, Alexandroupolis, Greece.

Methods

Patients receiving Belantamab mafodotin were examined before treatment  and every 3 weeks after treatment  for belantamab associated superficial keratopathy (BASK) . Follow-up protocol included uncorrected and best corrected distance visual acuity (UDVA and BSDVA) assessment, as well as cornea examination by slit lamp biomicroscopy and anterior segment optical coherence tomography (AS-OCT). The dosage regimen of the treatment was adjusted according to the ophthalmology examination outcomes.

Results

A 64-year-old female (patient 1), a 69-year-old male (patient 2) and a 61-year-old male (patient 3) were included in the study. All were diagnosed with RRMM and received monotherapy with Belantamab mafodotin. Ophthalmology examinations were conducted  according to the follow-up protocol. Patient 1 presented with decreased visual acuity three weeks after receiving the first dose. Slit lamp examination revealed microcystic-like epithelial changes (MECs) in the central cornea bilaterally. AS-OCT examination showed increased heterogeneous signal intensity and hyperreflective lesions. Patient 2 presented with decreased visual acuity after two cycles of Belantamab mafotidin.  Slit lamp examination revealed bilateral superficial micropunctate corneal staining with sodium fluorescein and microcystic-like epithelial changes (MECs). AS-OCT also revealed similar findings with patient 1. Patient 3 did not show any adverse events.

Conclusion

Detailed  follow-up of patients receiving Belantamab mafodotin could prevent and treat vision impairment caused by BASK. The Belantamab mafotidin dosage regimen should be adjusted according to the eye examination findings in order to prevent visual adverse effects.